Search
EN

Bio-Shield 2019-Ncov Total Immunoglobulins

Semi-quantitative ELISA test of 48 or 96 wells quantifying IgA, IgM, IgG antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens.
SKU: C1396

Register or Log In in order to request a quote

Register Login

Products specifications
TechnologyELISA
Sizes96 Tests
Semi-quantitative ELISA test of 48 or 96 wells quantifying IgA, IgM, IgG antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens.

GENERAL INFORMATION: Coronaviruses are enveloped, positive-sense and single-stranded RNA viruses with a nucleocapsid of helical symmetry and are composed of several proteins including the Spike (S), Envelope (E), Membrane (M) and Nucleocapsid (N) proteins. The S protein is very immunogenic with the Receptor Binding Domain (RBD) being the target of many neutralizing antibodies. The 2019 SARS-CoV-2 emerged in the Chinese province of Hubei (Wuhan) in December 2019 and has been declared a pandemic on 11 March 2020. This outbreak has spread rapidly, with millions of reported cases and thousands of deaths worldwide. Currently, there is no medication or vaccine available against infection with this new virus. Antibodies are produced by the immune system after an average of 7 days after infection. The Immunoglobulins M and A and G are produced in response of the infection and the Seroconversion for IgG and IgM occurs simultaneously or sequentially. Both IgG and IgM titers reach a plateau within 6 days after seroconversion. Within 19 days after symptom onset, all patients tested are positive for IgG against SARS-CoV-2. Serological testing may be helpful for the diagnosis of suspected patients with negative RT–PCR results (determining the number of cases of COVID-19) and for the identification of asymptomatic infections.

KIT CHARACTERISTICS:
-Semi-quantitative ELISA test with single-break strip plate with 48 wells (6 strips) or 96 wells (12 strips)
-Clinical Diagnostic Sensitivity 98,68%, 75/76 (CI: 0.93 to 0.9977),
-Clinical Diagnostic Specificity 100%, 86/86 (CI: 0.9572 to 1)
-Ιnternal validation results: 100%, 78/78 (CI: 0.9531 to 1) sensitivity & 100%, 667/667 (CI: 0.9943 to 1) specificity
-Test time: 120 min
-Compatible with automated ELISA systems
-Shelf Life: 12 months | Storage 2-8 °C
-The test has received the CE-IVD mark and therefore is approved for diagnostic use in the E.U.
Similar Products

Bio-Shield Surface Ag 2019-Ncov

The Bio-Shield Surface Ag 2019-nCov is an ELISA test for the measurement of SARS-CoV-2 Nucleocapsid Protein (NP) in swabs of common surfaces.
The test is intended for environmental swabbing of larger facilities & spaces and is adequate for up to 48 sample definitions at a time.

Bio-Shield 2019-Ncov Igg Immunoglobulin

Semi-quantitative ELISA test of 48 or 96 wells quantifying IgG antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens.

Bio-Shield 2019-Ncov Igm Immunoglobulin

Semi-quantitative ELISA test of 48 or 96 wells quantifying IgM antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens.

Grs Viral Dna/Rna Purification Kit

Purification of DNA and/or RNA: for DNA and RNA from cell-free media (serum, plasma, body fluids and the supernatant from viral infected cell cultures)

Rapid Test Surface Ag 2019-Ncov

The Rapid Surface Ag 2019-nCov is a rapid test for the detection of SARS-CoV-2 Nucleocapsid Protein Antigen (NP) in swabs of common surfaces, such as metal, plastic, glass, paper, and stainless steel. It is the first product for COVID-19 surface testing to utilize this innovative methodology.
The Rapid Surface Ag 2019-nCov is a valuable tool for several sectors enabling the companies to monitor and mitigate the spread of COVID-19 in their facilities and maintain a safe operating environment.